Roth MKM keeps a Buy rating and $7 price target on Gain Therapeutics (GANX) after the company received approval from Australian regulators to begin GT-02287 evaluation in Parkinson’s disease patients. The firm believes that the Phase 1b study will deliver positive findings regarding safety, preliminary biochemical efficacy, and tolerability, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.